Government pushes ahead with plan for cheaper drugs deal for NHSBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39300.405822.DB (Published 09 August 2007) Cite this as: BMJ 2007;335:273
- Nicholas Timmins, public policy editor, Financial Times
Ministers want to switch the way the NHS pays for the £8bn (€12bn; $16bn) worth of branded drugs that it buys each year. They want to move to a system in which drug prices are based on the benefits they bring to patients—and it seems they want to do so quickly.
The radical move comes after a report from the Office of Fair Trading (OFT) in February that recommended such a shift from 2010, when the current 50 year old pharmaceutical price regulation scheme (PPRS) becomes due for its five yearly renewal (BMJ 2007;334:383 doi: 10.1136/bmj.39133.543438.DB) .
The industry had been expecting a response but not last …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial